Source: Annual Congress 2004 - Chemotherapy, targeted therapies costs and outcomes
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Pesek, G. Krakorova (Plzen, Czech Republic). Gefitinib in the non small cell lung cancer treatment: contribution to prolongation and quality of survival. Eur Respir J 2004; 24: Suppl. 48, 1949

Member's Comments

No comment yet.

Related content which might interest you: Rates of treatment response and median survival in advanced non small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004 Tobacco exposure and survival in non small cell lung cancer patients treated with erlotinib Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004 Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Does long treatment delay affect survival in metastatic non-small cell lung cancer Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011 Long-term survival of the patients with advanced non small cell lung carcinomas after induction chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005 Does the incorporation of new generation cytotoxic agent improve the overall outcome in inoperable nonsmall cell lung cancer (NSCLC)? Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003 Impact of radiotherapy on survival rates in chemotherapy treated non small cell lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002 Survival of patients with relapsing small cell lung cancer (SCLC) after new line chemotherapy administration Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005 Overall survival analysis and characterization of an EGFR mutated non small cell lung cancer (NSCLC) population Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 Impact of radiotherapy on survival rates in chemotherapy treated small cell lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009 The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007 Non small cell lung cancer: options and outcome of treatment beyond second line Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Treatment of extensive-stage small cell lung carcinoma: current status and future prospects Source: Eur Respir J 2010; 35: 202-215 Year: 2010 One year survival differences of EGFR- and KRAS-mutated advanced non-small cell lung cancer (NSCLC) compared to the wildtype population Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012